Liquidation: BML Investment Partners, L.P.

Form Type: SCHEDULE 13D

Filing Date: 2025-04-24

Corporate Action: Liquidation

Type: New

Accession Number: 000137360425000063

Filing Summary: BML Investment Partners, L.P. holds 4,221,546 shares of Common Stock of ESSA Pharma Inc., representing 9.5% of the company. The investment was made using $6,476,584 of working capital. On April 24, 2025, the Reporting Person communicated with the Issuer's Board, advocating for an orderly winddown, liquidation, and capital return to shareholders, which they believe is in the best interests of the shareholders. No transactions were made in the Issuer's Common Stock during the 60 days preceding the filing of this Schedule. The shares were acquired solely for investment purposes, and the Reporting Persons continue to evaluate the Issuer's performance and future prospects. Additionally, there are no reported legal proceedings or arrangements among the Reporting Persons and any other party related to the Issuer's securities.

Document Link: View Document

Form Type: SCHEDULE 13D

Filing Date: 2025-04-16

Corporate Action: Liquidation

Type: New

Accession Number: 000137360425000060

Filing Summary: BML Investment Partners, L.P. reported beneficial ownership of 5,890,934 shares of Common Stock, representing 9.9% of Elevation Oncology, Inc., acquired for investment purposes. On April 16, 2025, they communicated to the Issuer's Board their belief that an orderly winddown, liquidation, and capital return is in the best interests of the shareholders. No recent transactions in Common Stock were reported, and the Reporting Persons reserve the right to make additional acquisitions or disposals based on market conditions. BML Investment Partners, L.P. holds this position through BML Capital Management, LLC, directed by Braden M. Leonard, who also confirmed that no criminal or civil proceedings have affected the Reporting Persons in the last five years.

Document Link: View Document